Privately held UNION therapeutics A/S has bought LEO Pharma A/S's range of phosphodiesterase type 4 (PDE4) inhibitors, including the investigational compound orismilast, which the Danish biotech aims to develop as a treatment for psoriasis and as a topical therapy for atopic dermatitis.
Under the Danish duo’s pact, announced on 21 July, UNION will pay upfront, development and commercial milestones of up to...








